Fulgent Genetics, Inc. Provides Earnings Guidance for the Second Quarter of 2023 and Full Year 2023
May 05, 2023 at 12:00 pm
Share
Fulgent Genetics, Inc. provided earnings guidance for the second quarter of 2023 and full year 2023. For the quarter, the company expects Core Revenue of approximately $62 million.
For the full year 2023, the company expects Core Revenue of approximately $250 million and GAAP loss of approximately $2.50 per share.
Fulgent Genetics, Inc. is a technology-based genetic company with a laboratory services business and a therapeutic development business. The Companyâs laboratory services business includes technical laboratory services and professional interpretation of laboratory results by licensed physicians. Its therapeutic development business is focused on developing drug candidates for treating a range of cancers using a nanoencapsulation and targeted therapy platform designed to improve the therapeutic window and pharmacokinetic profile (PK) profile of new and existing cancer drugs. Its technology platform for its laboratory services business includes gene probes, data suppression and comparison algorithms, learning software, and laboratory information management systems. The platform provides a test menu, the ability to rapidly develop and launch new tests and customizable test offerings. The Company also offers next-generation sequencing (NGS) services.
FULGENT GENETICS, INC. 
